Supernus Pharma (SUPN) Misses Q3 EPS by 6c, Revenues Miss; Lowers FY19 Sales Views, Reports Topline Data from Ph. 3 Study of SPN-810
Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.54, $0.06 worse than the analyst estimate of $0.60. Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)